CEL-SCI Corporation 10-Q Summary
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for CEL-SCI Corporation for the period ended December 31, 2001. The company is a biotechnology firm focused on the development of MULTIKINE, a product related to the human immunological defense system. The company has not yet realized significant product revenues and relies on financing activities to fund operations.
Key Financial Metrics
| Metric | Q4 2001 | Q4 2000 |
|---|---|---|
| Total Income | $176,244 | $249,808 |
| Net Loss | $(2,883,120) | $(2,543,489) |
| Net Loss Attributable to Common Stockholders | $(3,530,895) | $(2,543,489) |
| Loss Per Share (Basic & Diluted) | $(0.15) | $(0.12) |
| Cash and Cash Equivalents (Ending) | $2,475,572 | $3,713,027 |
| Net Cash Used in Operating Activities | $(491,938) | $(3,138,899) |
| Total Liabilities | $2,218,473 | Not Reported |
| Stockholders' Equity | $2,701,923 | Not Reported |
Note: The filing does not provide a clear comparative balance sheet for December 31, 2000, only the three-month operating results.
Material Changes vs. Prior Period
- Revenue Decline: Total income decreased by approximately 29% compared to the prior year quarter, primarily due to a significant drop in interest income ($25,337 vs. $183,211) resulting from a smaller cash position.
- Expense Increase: Research and development (R&D) expenses increased by $367,109 (18%) to $2,438,216, driven by costs associated with production at the Cambrex facility.
- Debt and Financing: The company incurred significant new debt obligations, including a $1,000,000 note payable to Cambrex Bioscience and $800,000 in proceeds from convertible notes (with a total agreement value of $1.6 million).
- Cash Flow Improvement: Net cash used in operating activities improved significantly to $(491,938) from $(3,138,899) in the prior year, aided by non-cash adjustments and a $1,000,000 R&D expense paid via note payable.
Outlook, Risks, and Management Commentary
- Liquidity Strategy: The company anticipates no significant product revenues for several years and remains dependent on short-term borrowings and equity sales. It maintains an equity line of credit with Paul Revere Capital Partners allowing up to $10 million in funding through June 2003.
- Manufacturing: The company utilizes a facility provided by Cambrex Bioscience for MULTIKINE production. A note payable of $1,159,000 was issued for facility usage, with $1,000,000 recorded as of December 31, 2001. The company expects short-term needs for this facility to be complete by January 10, 2002.
- Convertible Notes: New convertible notes bear 7% interest, are due in December 2003, and are secured by substantially all company assets. They contain restrictions on indebtedness, stock sales, and dividends.
- Risks: The company faces market risks related to interest rate fluctuations and the fair value of equity instruments. There is no assurance that other-than-temporary losses on investments will not materially impact future results.
Investor Verification Checklist
- Verify the status of the $1.6 million convertible note agreement and the timing of the second tranche of proceeds expected in January 2002.
- Confirm the repayment terms and interest accrual start date for the $1,159,000 Cambrex Bioscience note.
- Monitor the utilization of the $10 million equity line of credit with Paul Revere Capital Partners.
- Review the progress of MULTIKINE clinical studies and any updates on FDA approval timelines.
- Assess the impact of the beneficial conversion feature accretion ($579,695) on future net loss calculations.